Most Read Articles
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
3 days ago
The likelihood of having hearing loss (HL) is higher among patients with ankylosing spondylitis (AS) than those without, according to a new study.
Audrey Abella, 3 days ago
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.

EMPEROR-Reduced Trial: Overall Results for patients with HFrEF

03 Dec 2020
Heart failure (HF) is a debilitating, devastating, and fatal condition that has affected 64 million people worldwide.1,2 It is a significant global health problem with a mortality rate of 20% and 53% at one and five years from its initial diagnosis.3 An earlier trial, the DAPA-HF trial, showed that dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces the risk of cardiovascular death or hospitalization for heart failure regardless of the presence or absence of diabetes. Compared with the DAPA-HF trial, which includes patients with milder HF, the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure (EMPEROR-Reduced) trial was conducted among patients diagnosed with more severe disease.  

The EMPEROR-Reduced study is a phase III randomized, double-blinded, placebo-controlled, and event-driven trial. The trial was performed in 20 countries and was conducted on 3,730 patients diagnosed with class II, III, or IV HF and left ventricular EF of ≤40% with or without diabetes. This trial's participants were further limited to patients with an EF of >30% with a history of hospitalization due to HF within 12 months or had a high level of N-terminal prohormone of brain natriuretic peptide. The patients were randomized 1:1 and were followed up every 2 to 3 months.4,5  

The trial was designed to evaluate the efficacy and safety of empagliflozin (10 mg once daily), and its primary endpoint was the composite outcome of cardiovascular (CV) death or hospitalization for HF (hHF). The secondary endpoints included first and recurrent hHF and slope of decline in estimated glomerular filtration rate (eGFR) over time.5   

During a median follow-up of 16 months, the trial revealed that the combined risk of CV death and hHF was 25% lower for patients receiving empagliflozin. Results also showed that the first and recurrent hHF was reduced by 30% (HR 0.70, 95% CI 0.58–0.85, p<0.001) in the empagliflozin group. These findings also revealed that the annual rate of decline in eGFR was slower in the empagliflozin group (-0.55 vs. 0.28 mL/minute/1.73m2 of body surface area/year, p<0.001).5 These results were consistent with previous trials using the SGLT2 inhibitors in different aspects of the cardiovascular disease spectrum.

The safety profile that was seen in EMPEROR-Reduced supports the currently available safety profile of empagliflozin. There was no clinically meaningful difference in adverse events between empagliflozin and placebo groups in hypoglycemia, hypotension, and hypovolemia. It is also important to note that there are no cases of ketoacidosis that was noted in EMPEROR-Reduced.5  

Overall, the EMPEROR-Reduced Trial supports the use of SGLT2 inhibitors as part of the foundational treatment among patients with HF with reduced ejection fraction (HFrEF). This result is especially helpful in the Asian population, where there is a continuous rise in the prevalence of diabetes with HF. As Asian patients diagnosed with HFrEF have an increased burden of diabetes at a young age, higher prevalence of other comorbidities, and association with worse outcomes, this trial provides a basis for a much-needed treatment option that targets not only diabetes with mild HF but also diabetes with severe HF.5,6  

ph-wsp-001b

In a Boehringer Ingelheim, Inc-sponsored "Exclusive Virtual Press Conference for Southeast Asia" on September 3, 2020, Professor Faiez Zannad discussed the causes, symptoms, risk factors, and treatment methods in heart failure; background, study design, sample size, and results of the EMPEROR-Reduced trial and significance of the EMPEROR-Reduced trial results for heart failure patients, with or without diabetes in Southeast Asia. In the photo (L–R): Professor Faiez Zannad, Professor of Therapeutics and Cardiology at INSERM; and Rachel Lee, Head of Communications, ROPU SEASK, Boehringer Ingelheim.    

This material is for educational purposes only with the intent to communicate the results of the published EMPEROR-Reduced Trial. Empagliflozin is NOT indicated for the treatment of patients with heart failure with reduced ejection fraction in the Philippines. Please refer to the current local product information for the latest indication.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
3 days ago
The likelihood of having hearing loss (HL) is higher among patients with ankylosing spondylitis (AS) than those without, according to a new study.
Audrey Abella, 3 days ago
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.